384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen

What It Covers

STAT reporters interview Novo Nordisk CEO Mike Duster about obesity market competition and commercial strategy, followed by venture capitalist Bob Nelsen discussing FDA regulatory reform, China's biotech ascent, AI's impact on drug development, and intellectual property protection. Both guests address how pharmaceutical companies must adapt to accelerating technological change and global competition.

Key Questions Answered

• •DTC Market Growth: Novo Nordisk sees 10% of prescriptions coming from direct-to-consumer cash channels versus Eli Lilly's 30%, with cash channel growth rates significantly outpacing traditional insured channels. The company launched partnerships with LifeMD, Ro, Weight Watchers, and Amazon Pharmacy to meet patients where they already shop rather than forcing them to company-owned sites for Wegovy pill distribution.
• •M&A Discipline: Novo maintained a $10 billion bid for Metcera through 16 rounds of negotiation, refusing to increase despite competition from Pfizer. The company calculates precise asset valuations based on clinical data and timeline comparisons to existing pipeline, demonstrating that bad deals cost more than no deals. This disciplined approach extends across 100+ business development transactions completed over five years.
• •Regulatory Speed Competition: Australia approves human trials in five days versus FDA's 90-180 day timeline, with no evidence the longer process improves safety. The FDA's new gene and cell therapy manufacturing guidance signals movement toward faster approvals, but regulatory innovation remains an axis of global competition where the United States currently loses ground to Australia, Spain, and China.
• •AI Timeline Paradox: Biotech overestimates AI impact in six to twelve months while underestimating long-term disruption potential. AI capabilities in code generation increased five-fold between November and December, but biotech remains the hardest domain for AI application due to multiplicative probabilities and insufficient training data. The inflection point arrives when models receive enough biological data to independently invent novel mechanisms.
• •China IP Vulnerability: Twenty-five major China biotech deals originated from United States intellectual property, with companies increasingly filing patents later or maintaining stealth mode longer to protect innovations. Court cases take five to ten years to adjudicate, allowing large companies to wait out smaller innovators through expensive litigation regardless of merit, creating systematic vulnerability in the innovation ecosystem.
• •Healthcare Cost Rebalancing: Two billion people suffer from diabetes, obesity, or overweight conditions as drug development costs rise and healthcare systems approach insolvency from aging populations. This imbalance forces greater patient cost-sharing through higher copays, coverage restrictions, or direct cash payment models. Pharmaceutical companies must master both insurance and cash channels simultaneously, with potential employer-direct deals creating a third distribution model.